Market Cap: $9.01B
Market Cap: $9.01B
Open
$41.85
Prev. Close
$84.95
High
$44.11
Low
$41.37
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors.
Crinetics Pharmaceuticals, Inc. trades on the NASDAQ Global Select under the ticker CRNX, priced in USD.
Crinetics Pharmaceuticals, Inc. has a market capitalisation of $9.01B, based on its latest share price.
Over the past 52 weeks CRNX has traded between $25.83 and $84.95.
No. Crinetics Pharmaceuticals, Inc. does not currently pay a dividend.
Not yet. Crinetics Pharmaceuticals, Inc. is a pre-revenue company, so losses are expected while it develops its business. Cash on hand covers about 2.8 years of spending at the current burn rate.
The analyst consensus rating for CRNX is Buy. Analysts' average 12-month price target of $82.88 implies 2% downside.
R. Scott Struthers is the CEO of Crinetics Pharmaceuticals, Inc., which is headquartered in San Diego.
Generated automatically from reported financial data. General information only, not financial advice.